trending Market Intelligence /marketintelligence/en/news-insights/trending/gQzwccuq5upGR88gFQ6c3g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Novartis' Promacta shows long-term disease control in blood disorder trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Novartis' Promacta shows long-term disease control in blood disorder trial

Novartis AG's Promacta can be used as a long-term treatment option for adults with chronic/persistent immune thrombocytopenia, or ITP, trial results showed.

ITP is a rare and potentially serious blood clotting disorder caused by low platelet count which can result in bruising, bleeding and serious hemorrhaging that can be fatal.

Majority of the patients treated with eltrombopag, which is known as Promacta in the U.S. and Revolade outside the U.S., maintained a substantial clinical response in the EXTEND trial. Meanwhile, some patients were also capable of reducing or permanently stopping one or more concomitant ITP medications without the need for rescue therapy, many of which sustained reduction for at least 24 weeks.

The most common adverse events were headache, nasopharyngitis and upper respiratory tract infection. Promacta's safety profile was consistent with previous studies.